NCT01690741View on ClinicalTrials.gov

Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 19, 2017

Study Completion Date

December 19, 2017

Conditions
Cancer
Interventions
DRUG

Nerofe

Nerofe administered intravenously 3x/week

Trial Locations (1)

7661041

Kaplan Medical Center, Rehovot

All Listed Sponsors
lead

Immune System Key Ltd

INDUSTRY

NCT01690741 - Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies | Biotech Hunter | Biotech Hunter